{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:04:37Z","timestamp":1790024677460,"version":"4.0.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euo.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:26:51Z","timestamp":1790022411000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triplet Therapy in Metastatic Clear Cell Renal Cell Carcinoma: Time to Abandon Empiric, Biomarker-unselected Intensification?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":false,"given":"Javier","family":"Molina-Cerrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria G\u00f3mez","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.09.004_b0005","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.09.004_b0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.09.004_b0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.annonc.2026.02.011","article-title":"Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.09.004_b0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2025.10.010","article-title":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial","volume":"37","author":"Su\u00e1rez","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.09.004_b0025","unstructured":"Merck, Eisai. Merck and Eisai provide update on phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced renal cell carcinoma (RCC) [press release]; April 21, 2026. https:\/\/www.merck.com\/news\/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination-treatments-for-certain-patients-with-advanced-renal-cell-carcinoma-rcc\/."},{"key":"10.1016\/j.euo.2026.09.004_b0030","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.004_b0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.004_b0040","unstructured":"SWOG Cancer Research Network. S2419 (BioFront): Phase II\/III double-blinded trial of immune-based therapy with a live biotherapeutic (MO-03) or placebo for frontline therapy of advanced clear cell renal cell carcinoma. ClinicalTrials.gov identifier NCT07383441; 2026."},{"key":"10.1016\/j.euo.2026.09.004_b0045","unstructured":"CARE1 Pragmatic Clinical Trial: a phase III study comparing ICI-ICI versus ICI-VEGFR-TKI stratified by PD-L1 status in first-line metastatic clear-cell renal cell carcinoma. ClinicalTrials.gov identifier NCT06364631. 2024."},{"key":"10.1016\/j.euo.2026.09.004_b0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1470-2045(23)00319-4","article-title":"Common Sense Oncology: outcomes that matter","volume":"24","author":"Booth","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112600252X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112600252X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:26:55Z","timestamp":1790022415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112600252X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"alternative-id":["S258893112600252X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triplet Therapy in Metastatic Clear Cell Renal Cell Carcinoma: Time to Abandon Empiric, Biomarker-unselected Intensification?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}